Study in mice suggests drug could bring new benefits in treating depression by lifting mood within hours, plus offer sustained effectiveness
For someone with depression in the midst of a crisis, there is no time to waste. Yet time is exactly what currently-available antidepressants require to take effect—often on the order of weeks.
A new study suggests a fast-acting antidepressant may be on the horizon. In mice, the drug produces evidence of a mood lift within 24 hours and then continues working for sustained relief.
“What makes this study unique and exciting is that in the same drug we seem to have both of the properties you want in an antidepressant—both rapid and sustained effects,” said Jeffery Talbot, Ph.D., director of the Research Center on Substance Abuse and Depression at Roseman University of Health Sciences and one of the study’s lead investigators.
Though many drugs are currently available to treat people with depression, existing drugs do not work quickly, and they do not work for everyone. “Many people with depression simply don’t respond to available medications,” said Talbot. “There’s still a real need for new antidepressants.”
The drug, referred to by Talbot as its coded name MI-4 and better known among scientists as Ro-25-6981, has been shown by previous researchers to cause a rapid antidepressant effect in animals by blocking one of the brain’s signaling chemicals. But until now, researchers were not aware of the full spectrum of its antidepressant properties.
The new study bolsters the evidence for MI-4’s rapid effect and adds an exciting twist: MI-4 also works in the long term. Moreover, it may accomplish its long-term effects through a three-pronged approach known as triple reuptake inhibition, which refers to a drug’s ability to simultaneously increase the levels of three key chemicals in the brain that are known to affect mood and feelings of pleasure—dopamine, norepinephrine and serotonin. Most depression drugs only target one of these chemicals, which may explain why they are not effective in all patients.
The researchers found MI-4 via “virtual screening,” a method that uses computer modeling to find drugs that are likely to interact with particular receptors in the brain. “From looking at its structure, one would never have guessed that this drug interacts with the same monoamine transporter proteins as does Paxil or cocaine, but it does. That speaks to the ‘needle in a haystack’ detection power of the virtual screening methodology,” said Christopher Surratt, Ph.D., a professor of pharmacology working on this aspect of the study at Duquesne University.
Following the virtual screening, the researchers tested MI-4’s effects in cell cultures and then in mice. In addition to providing new evidence of its antidepressant properties, the study shows MI-4 would be unlikely to become addictive.
Depression is one of the most common mental illnesses in the world, affecting about 20 million people in the United States. Causing persistent sadness and loss of energy, it can take an enormous toll on a person’s ability to work or have healthy personal relationships and is a leading cause of suicide.
Antidepressants are some of the most commonly prescribed medications, with 264 million prescriptions written for antidepressants in 2011 totaling more than $11 billion in sales.
The Latest on: Antidepressant
via Google News
The Latest on: Antidepressant
- VistaGen's (VTGN) Major Depressive Disorder Drug Disappointson November 15, 2019 at 7:55 am
The ELEVATE study was a phase II, double-blind, placebo-controlled, multi-center, sequential parallel comparison design study that evaluated the safety, tolerability and efficacy of AV-101 as an ...
- Antidepressant Drugs Market Projected to Deliver Greater Revenues during the Forecast Period until 2024on November 15, 2019 at 2:09 am
Nov 15, 2019 (AmericaNewsHour) -- Global Antidepressant Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast: 2018-2024 Overview: Depression is a serious mental illness affecting ...
- How Do You Know If Your Antidepressants Are Working?on November 14, 2019 at 4:17 pm
Plus, you’ve been experiencing nausea right after taking the medication. If you’re asking yourself, “Is this antidepressant even working?” and feeling unsure, you’re not alone. Antidepressants affect ...
- Antidepressants Pollute Bodies Of Water, Negatively Affect Fishon November 14, 2019 at 3:52 pm
"Prozac pollution" remains a potentially dangerous long-term problem that fish and aquatic wildlife still have to contend with. Prozac (generic name fluoxetine) remains a popular antidepressant used ...
- Antidepressant Drugs Market 2019 Precise Outlook – Allergan, Forest laboratories, Takeda, Novartis, Eli Lillyon November 8, 2019 at 4:49 am
Nov 08, 2019 (Market Insight Reports via COMTEX) -- The report titled "Global Antidepressant Drugs Market - Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and ...
- Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metaboliteson November 7, 2019 at 9:38 am
Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and ...
- What Happened to Lithium? Antidepressant Augmentation in Clinical Settingson October 31, 2019 at 5:00 pm
Patients were included in the study if they had received a diagnosis of depression in specialty mental health settings and an antidepressant medication during fiscal year 2002 (Oct. 1, 2001, through ...
- Anti-inflammatory agents can effectively and safely curb major depressive symptoms, study suggestson October 29, 2019 at 5:23 am
The researchers therefore set out to review the available evidence and pool the data to see if anti-inflammatory agents work better than dummy (placebo) treatment either alone or when used as add-on ...
- When Is an Antidepressant Not Really an Antidepressant?on October 28, 2019 at 7:02 pm
Now, I’m seen by a local doctor, and most days, it’s just easier to get my meds filled locally.) Of course, I knew it was an antidepressant. A quick Google search will tell you that. However, Google ...
- Antidepressant Doesn't Ease Autism's Compulsionson October 22, 2019 at 12:18 pm
TUESDAY, Oct. 22, 2019 (HealthDay News) -- The commonly used antidepressant Prozac doesn't appear to help reduce obsessive-compulsive behavior in children and teens with autism, new research suggests.
via Bing News